Alkyl Quinolone Biomarkers for Pseudomonas aeruginosa Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic techniques for Pseudomonas aeruginosa infection, such as traditional microbiological methods and PCR-based assays, are inadequate for early detection and often provide false positives, failing to effectively manage the infection and its impact on respiratory diseases like cystic fibrosis and COPD, which leads to accelerated lung function decline and high treatment costs.
Innovation Solution
Determining the level of alkyl quinolones or their metabolites produced by Pseudomonas aeruginosa or related species in a subject's sample, using methods like mass spectrometry or biosensors, to assess infection status and monitor treatment efficacy, allowing for early detection and personalized interventions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional microbiological techniques are used for diagnosis, then the method is simple and widely available, but the detection sensitivity is insufficient and early infection cannot be detected
Solution Approach 1:
The patent replaces traditional mechanical microbiological culture methods with mass spectrometry technology to detect alkyl quinolone biomarkers. This substitution enables detection at much lower concentrations (early infection stage) while providing objective quantitative data, resolving the contradiction between detection sensitivity and method complexity.
Solution Approach 2:
The patent introduces alkyl quinolone biomarkers as intermediary substances that mediate between the bacterial infection and the detection system. These biomarkers are detectable before bacterial culture becomes positive, enabling early detection while using sophisticated mass spectrometry equipment.
2Measurement precision
If PCR-based assays are used for diagnosis, then detection capability is enhanced, but false positive results occur due to amplification of bacterial contamination
Solution Approach 1:
The patent converts the harmful effect of bacterial contamination (which causes false positives in PCR) into a beneficial signal. By detecting alkyl quinolone biomarkers produced by bacteria, the method specifically identifies actual infections rather than contamination, as these biomarkers are only produced by metabolically active bacteria causing true infection.
Solution Approach 2:
The patent changes the detection parameter from bacterial DNA amplification (PCR) to metabolic biomarker detection (alkyl quinolones). This parameter change fundamentally alters what is being measured, detecting bacterial metabolic activity rather than genetic material, thereby eliminating false positives from contamination while maintaining high detection capability.
3Measurement precision
If serological measures are used for diagnosis, then research has been ongoing for 20 years, but no clear consensus on clinical role exists
Solution Approach 1:
The patent extracts the diagnostic function from complex serological antibody measurements and focuses specifically on detecting alkyl quinolone biomarkers in body fluids. This extraction of the essential diagnostic function provides a clear, actionable clinical tool with immediate applicability, avoiding the decades-long consensus process required by serological methods.
4Loss of time
If early detection methods are implemented, then treatment can be initiated earlier to prevent lung function decline, but current methods lack the sensitivity for early detection
Solution Approach 1:
The patent enables preliminary detection of infection by measuring alkyl quinolone biomarkers before traditional culture methods become positive. This preliminary action allows clinicians to initiate eradication therapy at the earliest possible stage, preventing progression to chronic infection and preserving lung function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables sensitive and accurate detection of Pseudomonas aeruginosa infection at levels below conventional microbiological thresholds, facilitating timely eradication, improving treatment outcomes, and reducing healthcare costs by providing a biomarker for infection status and treatment monitoring.
Implementation Method 1
determining the level of one or more alkyl quinolones or metabolites thereof produced by P. aeruginosa or a related species in the sample
Implementation Method 2
using methods like mass spectrometry or biosensors, to assess infection status
Data Source
AI summary
A method of determining the P. aeruginosa or related species infection status of a subject comprising: (i) providing a sample of material obtained from the subject; (ii) determining the level of one or more alkyl quinolones or metabolites thereof produced by P. aeruginosa or a related species in the sample